Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Puma Biotechnology (PBYI) Net Margin (2017 - 2025)

Historic Net Margin for Puma Biotechnology (PBYI) over the last 9 years, with Q3 2025 value amounting to 16.23%.

  • Puma Biotechnology's Net Margin fell 89900.0% to 16.23% in Q3 2025 from the same period last year, while for Sep 2025 it was 14.11%, marking a year-over-year increase of 45600.0%. This contributed to the annual value of 10.07% for FY2024, which is 9000.0% up from last year.
  • Puma Biotechnology's Net Margin amounted to 16.23% in Q3 2025, which was down 89900.0% from 11.17% recorded in Q2 2025.
  • Puma Biotechnology's Net Margin's 5-year high stood at 25.23% during Q3 2024, with a 5-year trough of 96.6% in Q3 2021.
  • Its 5-year average for Net Margin is 0.66%, with a median of 6.46% in 2025.
  • Its Net Margin has fluctuated over the past 5 years, first crashed by -346100bps in 2021, then surged by 959700bps in 2022.
  • Puma Biotechnology's Net Margin (Quarter) stood at 7.63% in 2021, then plummeted by -184bps to 6.4% in 2022, then skyrocketed by 366bps to 17.0% in 2023, then rose by 22bps to 20.7% in 2024, then decreased by -22bps to 16.23% in 2025.
  • Its Net Margin was 16.23% in Q3 2025, compared to 11.17% in Q2 2025 and 6.46% in Q1 2025.